LINC02253: A Key Regulator of Cell Growth and Death (G107984764)

Target Name: LINC02253

NCBI ID: G107984764

Other Name(s): LINC02253 variant X1 | LINC02253 variant X2 | long intergenic non-protein coding RNA 2253 | Long intergenic non-protein coding RNA 2253, transcript variant X1 | Long intergenic non-protein coding RNA 2253, transcript variant X2 | Long intergenic non-protein coding RNA 2253, transcript variant X3 | LINC02253 variant X3

LINC02253: A Key Regulator of Cell Growth and Death

LINC02253 (LINC02253 variant X1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the defining features of LINC02253 is its unique structure. It is a transmembrane protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain is involved in cell adhesion and interaction, while the transmembrane region is responsible for the protein's ability to interact with other cells and molecules. The intracellular domain is where the protein interacts with its ligands and targets inside the cell.

LINC02253 has been shown to play a role in a number of important biological processes, including cell growth, migration, and apoptosis (programmed cell death). It is a negative regulator of the TGF-β pathway, which is a well-known regulator of cell growth and differentiation. TGF-β is involved in the development and maintenance of tissues, and is often aberrantly activated in a variety of diseases, including cancer.

LINC02253 has also been shown to be involved in the regulation of cell survival and proliferation. It has been shown to play a role in the cell cycle, and has been shown to interact with several key cell cycle proteins, including cyclin D1 (CDK4) and p21 (CDK2). CDK4 and CDK2 are involved in the G1 phase of the cell cycle, and play important roles in regulating cell growth and differentiation.

In addition to its role in cell growth and differentiation, LINC02253 has also been shown to be involved in the regulation of cell death. It has been shown to play a role in the regulation of apoptosis, which is a natural and necessary process for the elimination of damaged or dysfunctional cells. LINC02253 has been shown to interact with several apoptosis-related proteins, including Bcl-2 (Bcl2/Ago1) and caspase 3. Bcl-2 and caspase 3 are involved in the formation of the apoptotic vacuole, which is a key step in the process of cell death.

LINC02253 has also been shown to be involved in the regulation of neurodegenerative diseases. It has been implicated in the development and progression of a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. LINC02253 has been shown to interact with several neurodegenerative disease-related proteins, including tau (Tau) and beta-amyloid (beta-amyloid). Tau and beta-amyloid are involved in the development and progression of neurodegenerative diseases, and have been implicated in the development of these diseases.

In conclusion, LINC02253 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its unique structure and involvement in a number of important biological processes make it an attractive target for research and development of new treatments. Further studies are needed to fully understand the role of LINC02253 in disease and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2253

More Common Targets